Mankind ipo gmp

Mankind Pharma has been able to hold firm, ignoring the correction in the broader markets. If one goes by the signals from the grey market, the listing contender has been seen standing tall, holding its premium and gearing up to deliver a decent listing pop to the investors. Last heard, Mankind Pharma's shares were commanding a premium of Rs 100-110 in the grey market, a premium of about 10 per cent over its issue price of Rs 1,080. The pharmaceutical company is set to make its debut at Dalal Street on Monday, May 08, even as the listed markets shed over a per cent on Friday. Dealers tracking the grey market said the investors can expect a mild listing pop of 10-15 per cent but one can hold it for a longer run as well. The mega-issue received a strong response from the investors, led by the institutions, while retailers kept off the bay due to hammering of recent pharma and big-ticket IPOs. An avid tracker of unofficial markets on the condition of anonymity said that Mankind Pharma is a decent bet from a defensive space, which was offered at moderate valuations compared to the peers. "The muted response from the retailers and large size of issue were only concerns for the it," he said. Incorporated in 1991, Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products. It has over 36 brands across the segments Including anti-infectives, cardiovascular, gastrointesti...

Mankind Pharma, the manufacturer of the top-selling condom brand Manforce Condoms, is going to open its Rs 4,326-crore initial public offering (IPO) next week, between April 25 and April 27. The subscription window for anchor investors will open on April 24. The Mankind Pharma The grey market premium (GMP) of Mankind Pharma IPO on Wednesday stood at Rs 80. It means shares of Mankind Pharma were trading at Rs 1,160, or 7.41 per cent up over the upper price of the IPO price band, at the grey market (Rs 1,080 + Rs 80). This indicates a decent listing for the Mankind Pharma IPO next week. Mankind Pharma IPO: Key Dates The IPO of private equity firm ChrysCapital-backed Mankind Pharma will be available for public subscription between April 25 and 27. Anchor investors will be allowed to participate a day before — April 24. The share allotment will take place May 3. However, the shares will be listed at both the NSE and the BSE. Mankind Pharma IPO: Price Band, Lot Size The IPO, which is entirely an offer for sale (OFS) of 40.06 million equity shares by promoters and other existing shareholders, has seen its price band fixed at Rs 1,026-1,080 per share. In the Rs 4,326-crore IPO, a bidder could bid for a minimum of one lot and maximum 13 lots. A lot will have Mankind Pharma’s 13 shares. Mankind Pharma IPO: Quotas The initial public offering will have a reservation of 35 per cent for retail investors, while qualified institutional buyers (QIBs) will be able to participate in 50 per ...

The initial public offering (IPO) of Mankind Pharma was subscribed 14% far on Day 1. While retail investors’ part was subscribed 10%, non-institutional investors’ (NIIs’) portion was subscribed 33%. QIB category, on the other hand, was subscribed 8%. According to market sources, the grey market premium (GMP) of Mankind Pharma is around Rs 90-95 on Tuesday — higher than the previous day. The Rs 4,300-crore IPO, which is completely an offer for sale (OFS), will be available for public to bid till April 27. Investors can bid for 13 shares in 1 lot and in multiples thereof. Under the OFS, around 40 million shares will be offloaded by promoters and selling shareholders. The company has set a price band of Rs 1,026-1080 per share. ICICI Direct has a "subscribe" recommendation to the issue as it benefits from its strong foothold in domestic branded formulations with emphasis on affordable product offerings. Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales and third-largest in terms of sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilities across the country. As of December 2022, the company had a team of over 600 scientists and a dedicated in-house R&D centre with four units located at IMT Manesar, Gurugram and Thane. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Econo...

Mankind Mankind IPO GMP Today Mankind Pharma’s shares are currently trading at a premium of a whopping Rs 108 or 10 per cent up in the grey market, over the upper band of Rs 1,080 a share. So, the shares in the grey market are currently trading at Rs 1,188 apiece, on May 8. It indicates that the company’s shares are expected to be listed at a good premium over its issue price on May 8, 2023. The premium gets fluctuated based on the sentiments in the markets. On the company’s IPO price, analysts at brokerage firm Anand Rathi have said, “At the high (Rs 1,080) of the issue price band, the stock is valued at about 30x FY22 EPS of Rs 36. Pharma companies quote at an average P/E of 25x/22x FY24e/FY25e. We expect the company’s strong set of brands, focused approach to its chronic portfolio via recent acquisitions, launches and differentiated pipeline products to be key positives. However, risks are addition of NLEM lists, rise in raw material prices." Mankind Pharma IPO: Basic Details Mankind Pharma is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparation categories. It has a pan-India marketing presence and operates 25 manufacturing facilities across the...

Mankind Pharma Limited offers a IPO issue size of 40,058,844 equity shares worth of Rs 4326.36 Cr. Subscription of this IPO is opening from 25 Apr 2023 to 27 Apr 2023. The face value of the equity share is Rs 1 per share and the issue price band is ranging from Rs 1026 to Rs 1080 per share. and the minimum lot size is 13 shares and their multiples. Stay updated with us to know more about the Mankind Pharma Limited IPO Review including company overview, financial, live subscription, allotment, GMP, and more. Mankind Pharma IPO Details IPO Issue Opening Date: 25th Apr 2023 IPO Issue Closing Date: 27th Apr 2023 IPO Issue Price: ₹1026-1080 Per Share DRHP: Download DRHP RHP: Download RHP Anchor List: Download Anchor List IPO Listing At: BSE, NSE Retail Quota: Not less than 35% of the Net Issue IPO Issue Type: Book Build Issue IPO Issue Size: ₹4326.36 Cr Offer for Sale: ₹4326.36 Cr Face Value: ₹1 Per Equity Share IPO Discount: TBD Promoter Holding Pre IPO: 79.00% Promoter Holding Post IPO: 76.50% Allotment Status: Allotment Status BSE Code: 543904 NSE Code: MANKIND IPO Live GMP Mankind Pharma IPO Important Dates In this section we have covered all important dates related to Mankind Pharma IPO. Dates are updated as they are announced. The most noted dates are IPO start date and IPO end date, which one should use to participate in IPO. Mankind Pharma IPO important dates IPO Activity Date Basis of Allotment Date* 3rd May 2023 Refunds Initiation* 4th May 2023 Credit of Shares to Dem...

Mankind Pharma IPO description – Mankind Pharma is India’s fourth-largest pharmaceutical company in terms of domestic sales and second-largest in terms of sales volume in FY 2022. The company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company is focused on the domestic market which contributed 97.6% of its total revenue from operations for FY 2022. Mankind Pharma has created 36 brands in its pharmaceutical business that have each achieved over INR 50 crore in domestic sales in FY 2022. The company is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. As of 31 March 2022, Mankind Pharma operated 23 manufacturing facilities across India and had 2,181 manufacturing personnel. Its formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives, other over-the-counter products. The company had a team of over 600 scientists and dedicated in-house R&D center at IMT Manesar, Haryana. • • • • • • • • • • • • Mankind Pharma IPO Details Mankind Pharma IPO Dates 25 – 27 April 2023 Mankind Pharm...

Mankind Pharma Mankind Pharma develops and manufactures a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. Mankind Pharma IPO Subscription Data (as of 5:00 PM Apr 25, 2023) QIB – 0.08x, NII – 0.33x - , Retail – 0.10x Total – 0.14x Mankind Pharma IPO Dates The offer opened for the public on April 25, while the closing date would be April 27, 2023. The company will open its anchor book, a part of QIB portion, on April 24, a day before opening IPO. Mankind Pharma IPO Price The company has fixed Mankind Pharma IPO price band at Rs 1026 to Rs 1080 per equity share. Mankind Pharma IPO Offer Size The maiden public comprises only an offer for the sale of over 4 crore equity shares by promoters and investors, while there is no fresh issue portion. The total fundraising by the company would be Rs 4,110.03 at the lower price band, and Rs 4,326.35 crore at the higher band. Promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora will be offloading over 1 crore shares via offer for sale, and the rest of the shares in the OFS will be sold by investors Cairnhill CIPEF, Cairnhill CGPE, Beige, and Link Investment Trust. Mankind Pharma IPO Objectives of Issue The main objectives of the offer would be to carry out the offer for sale by the selling shareholders and achieve the benefits of listing the equity shares on the stock exchanges. All the money raised via public issues will go to selling s...

Mankind Pharma Mankind Pharma develops and manufactures a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. Mankind Pharma IPO Subscription Data (as of 5:00 PM Apr 25, 2023) QIB – 0.08x, NII – 0.33x - , Retail – 0.10x Total – 0.14x Mankind Pharma IPO Dates The offer opened for the public on April 25, while the closing date would be April 27, 2023. The company will open its anchor book, a part of QIB portion, on April 24, a day before opening IPO. Mankind Pharma IPO Price The company has fixed Mankind Pharma IPO price band at Rs 1026 to Rs 1080 per equity share. Mankind Pharma IPO Offer Size The maiden public comprises only an offer for the sale of over 4 crore equity shares by promoters and investors, while there is no fresh issue portion. The total fundraising by the company would be Rs 4,110.03 at the lower price band, and Rs 4,326.35 crore at the higher band. Promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora will be offloading over 1 crore shares via offer for sale, and the rest of the shares in the OFS will be sold by investors Cairnhill CIPEF, Cairnhill CGPE, Beige, and Link Investment Trust. Mankind Pharma IPO Objectives of Issue The main objectives of the offer would be to carry out the offer for sale by the selling shareholders and achieve the benefits of listing the equity shares on the stock exchanges. All the money raised via public issues will go to selling s...

Mankind Pharma has been able to hold firm, ignoring the correction in the broader markets. If one goes by the signals from the grey market, the listing contender has been seen standing tall, holding its premium and gearing up to deliver a decent listing pop to the investors. Last heard, Mankind Pharma's shares were commanding a premium of Rs 100-110 in the grey market, a premium of about 10 per cent over its issue price of Rs 1,080. The pharmaceutical company is set to make its debut at Dalal Street on Monday, May 08, even as the listed markets shed over a per cent on Friday. Dealers tracking the grey market said the investors can expect a mild listing pop of 10-15 per cent but one can hold it for a longer run as well. The mega-issue received a strong response from the investors, led by the institutions, while retailers kept off the bay due to hammering of recent pharma and big-ticket IPOs. An avid tracker of unofficial markets on the condition of anonymity said that Mankind Pharma is a decent bet from a defensive space, which was offered at moderate valuations compared to the peers. "The muted response from the retailers and large size of issue were only concerns for the it," he said. Incorporated in 1991, Mankind Pharma develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products. It has over 36 brands across the segments Including anti-infectives, cardiovascular, gastrointesti...

Mankind Pharma, the manufacturer of the top-selling condom brand Manforce Condoms, is going to open its Rs 4,326-crore initial public offering (IPO) next week, between April 25 and April 27. The subscription window for anchor investors will open on April 24. The Mankind Pharma The grey market premium (GMP) of Mankind Pharma IPO on Wednesday stood at Rs 80. It means shares of Mankind Pharma were trading at Rs 1,160, or 7.41 per cent up over the upper price of the IPO price band, at the grey market (Rs 1,080 + Rs 80). This indicates a decent listing for the Mankind Pharma IPO next week. Mankind Pharma IPO: Key Dates The IPO of private equity firm ChrysCapital-backed Mankind Pharma will be available for public subscription between April 25 and 27. Anchor investors will be allowed to participate a day before — April 24. The share allotment will take place May 3. However, the shares will be listed at both the NSE and the BSE. Mankind Pharma IPO: Price Band, Lot Size The IPO, which is entirely an offer for sale (OFS) of 40.06 million equity shares by promoters and other existing shareholders, has seen its price band fixed at Rs 1,026-1,080 per share. In the Rs 4,326-crore IPO, a bidder could bid for a minimum of one lot and maximum 13 lots. A lot will have Mankind Pharma’s 13 shares. Mankind Pharma IPO: Quotas The initial public offering will have a reservation of 35 per cent for retail investors, while qualified institutional buyers (QIBs) will be able to participate in 50 per ...